What Is Retatrutide Research Peptide? A Simple Overview for Labs and Researchers
What Is Retatrutide Research Peptide? A Simple Overview for Labs and Researchers
Last Updated: March 19, 2026 | Reading Time: ~8 minutes
Disclaimer: Retatrutide (LY3437943) is an investigational research peptide. It is not approved by the FDA or any regulatory authority for use in humans or animals. All Palmetto Peptides products are sold exclusively for in vitro laboratory research by qualified professionals. Nothing here constitutes medical advice or a treatment recommendation.
The Short Answer
Retatrutide, research designation LY3437943, is a synthetic peptide that activates three hormone receptors at once: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). That triple action is why researchers and scientific publications often call it a "triple agonist" or "triple incretin receptor agonist."
It is currently the most advanced compound of its class in clinical development, with completed Phase 2 trials and ongoing Phase 3 trials under Eli Lilly's TRIUMPH program. As a research peptide, it offers laboratories a tool to study what happens when all three of these metabolic pathways are activated simultaneously.
Where Did Retatrutide Come From?
The story starts with a question that metabolic researchers had been wrestling with for years: if one receptor agonist is useful and two is better, could three produce something genuinely different?
The incretin class of peptide-based compounds has its roots in the discovery that gut-derived hormones released after meals play a significant role in regulating insulin secretion, appetite, and energy metabolism. GLP-1 and GIP are both incretin hormones, meaning they are released from intestinal cells in response to food and act on the pancreas to promote insulin release in a glucose-dependent manner.
Glucagon, by contrast, had traditionally been viewed as insulin's opponent — the hormone that raises blood sugar when it drops too low. But researchers came to understand that glucagon does far more than that, particularly at the liver, where it drives fat oxidation and energy expenditure. Adding glucagon receptor activity to an incretin-based compound raised the hypothesis that you could reduce food intake (via GLP-1 and GIP pathways) while simultaneously increasing the amount of energy the body burns (via glucagon's hepatic effects).
Eli Lilly's scientists designed retatrutide to test that hypothesis. The 2022 Cell Metabolism paper by Coskun et al. described the compound's discovery, its preclinical receptor binding profile, and early evidence that it outperformed dual agonists in rodent models. From there, the compound moved into human trials, where Phase 2 data published in the New England Journal of Medicine and The Lancet in 2023 demonstrated its clinical research profile in detail.
You can read the full breakdown of those trial results in our Complete Guide to Retatrutide Research Peptide.
What Makes It a "Triple Agonist"?
A receptor agonist is a molecule that binds to a receptor and activates it, triggering a downstream biological response. Most peptide research compounds in the incretin class are designed to activate one or two receptors.
Retatrutide activates three:
GIP Receptor (GIPR): The most potent binding interaction for retatrutide. GIP is a gut hormone released after eating that contributes to insulin secretion and may influence energy storage and appetite. Retatrutide's EC50 at the human GIPR is approximately 0.064 nM, making it more potent here than at the other two receptors.
GLP-1 Receptor (GLP-1R): The same receptor targeted by semaglutide and also engaged by tirzepatide. GLP-1 receptor activation promotes insulin secretion, suppresses glucagon release after meals, slows gastric emptying, and signals satiety in the brain. Retatrutide's EC50 at GLP-1R is approximately 0.775 nM.
Glucagon Receptor (GCGR): This is the addition that distinguishes retatrutide from everything else in the incretin class. Glucagon receptor activation at the liver increases fatty acid oxidation and lipolysis — meaning the liver burns more fat for energy. It also appears to have appetite-suppressing effects through central nervous system pathways. Retatrutide's EC50 at GCGR is approximately 5.79 nM.
Receptor Potency Overview
| Receptor | EC50 (Human, In Vitro) | What It Influences |
|---|---|---|
| GIPR | ~0.064 nM | Insulin secretion, adipose signaling |
| GLP-1R | ~0.775 nM | Satiety, gastric motility, insulin |
| GCGR | ~5.79 nM | Hepatic fat oxidation, energy expenditure |
In vitro data. Source: Coskun et al., Cell Metabolism, 2022.
How Is It Different from Other Peptides in the Incretin Class?
This is the question researchers most often ask when they first encounter retatrutide. The clearest way to answer it is by comparison:
Semaglutide targets one receptor: GLP-1R only. It has a well-established research profile and is the class benchmark for single-receptor GLP-1 agonism. See our Semaglutide Research Peptide page for details.
Tirzepatide targets two receptors: GIP and GLP-1. It is an FDA-approved dual agonist and the most direct predecessor to retatrutide in terms of mechanism. It does not have meaningful glucagon receptor activity. See our Tirzepatide Research Peptide page for more.
Retatrutide adds the third receptor. The glucagon receptor engagement is what makes it structurally and pharmacologically unique. For researchers studying metabolic disease, liver fat biology, or energy expenditure, that additional mechanism matters.
For a detailed side-by-side comparison, see our supporting articles: - Retatrutide vs Tirzepatide: Main Differences for Lab Use - Retatrutide vs Semaglutide: What Labs Need to Compare
What Is It Used for in Research?
Because retatrutide is investigational, the body of published research reflects what scientists have studied in formal clinical trials and preclinical models. The primary research applications based on published literature include:
Metabolic disease modeling: Phase 2 trials examined retatrutide's effects on body weight, blood glucose, HbA1c, and lipid parameters in both diabetic and non-diabetic populations.
Liver fat biology: A 2024 Nature Medicine substudy found up to 82% relative reduction in liver fat content at 24 weeks in participants with metabolic dysfunction-associated steatotic liver disease (MASLD), making hepatic fat research an especially relevant application.
Cardiometabolic marker research: The Phase 2 type 2 diabetes trial reported improvements in triglycerides, non-HDL cholesterol, and systolic blood pressure alongside glycemic outcomes.
Neurodegeneration preclinical work: A 2024 PMC publication found that retatrutide and related multi-agonist peptides demonstrated neuroprotective and anti-inflammatory properties in cellular models of neurodegeneration, an early but notable area of investigation.
Comparative mechanism studies: Because retatrutide engages all three receptors while tirzepatide engages only two and semaglutide engages only one, it serves as a useful tool for dissecting the specific contribution of each receptor pathway to observed metabolic outcomes.
What Form Does It Come In for Research Use?
Research-grade retatrutide is supplied as a lyophilized (freeze-dried) powder in sealed vials. This format provides maximum stability during shipping and long-term storage. Before use in any in vitro experiment, it must be reconstituted with an appropriate sterile diluent.
Palmetto Peptides offers retatrutide in research-grade format with a certificate of analysis confirming purity. Visit our Retatrutide product page for current vial sizes and specifications.
For information on handling and preparation, see our detailed guide: How to Reconstitute Retatrutide Research Peptide: Easy Step-by-Step for Labs.
What Is Its Current Regulatory Status?
Retatrutide is an investigational compound. As of March 2026:
- It has not received FDA approval for any indication
- It is being evaluated in Phase 3 trials under Eli Lilly's TRIUMPH program across seven clinical areas including obesity, type 2 diabetes, MASLD, and knee osteoarthritis
- Phase 3 topline data from the TRIUMPH-4 osteoarthritis trial was reported as positive in 2025
- It is legal to purchase and use for licensed laboratory research purposes in the United States
It is not legal to use for human therapeutic purposes, self-administration, or any clinical application outside of FDA-authorized trials.
Summary
Retatrutide is a 39-amino-acid synthetic research peptide that simultaneously activates the GIP, GLP-1, and glucagon receptors. Developed by Eli Lilly, it is the first triple incretin receptor agonist with published Phase 2 human data and is currently in Phase 3 clinical trials. It is available as a research-grade peptide for in vitro laboratory use by qualified researchers. It is not FDA approved and is not intended for human or veterinary use.
Frequently Asked Questions
Q: What is retatrutide in simple terms? It is a synthetic research peptide designed to activate three hormone receptors: GIP, GLP-1, and glucagon. This triple activation is what makes it scientifically distinct from earlier compounds in the incretin class.
Q: Who made retatrutide? Eli Lilly and Company developed retatrutide (LY3437943). The discovery was first published in Cell Metabolism in 2022.
Q: Is retatrutide the same as Ozempic or Mounjaro? No. Semaglutide (Ozempic) activates GLP-1R only. Tirzepatide (Mounjaro) activates GIP and GLP-1R. Retatrutide adds glucagon receptor activity, making it a triple agonist. None of these compounds are interchangeable for research purposes.
Q: Can I use retatrutide research peptide in my lab? If you are a qualified researcher conducting legitimate in vitro studies, yes. Palmetto Peptides sells retatrutide for that purpose. It is not for human use, veterinary use, or any clinical application outside of FDA-authorized trials.
Q: Is retatrutide legal to buy? Yes, for research purposes. It is legal to purchase as a research chemical in the United States for laboratory use. Personal use or self-administration is not a lawful application.
Peer-Reviewed Citations
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.e9.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity -- A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet. 2023;402(10401):529-544.
- Liu Q, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:72.
- Nicze M, et al. Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy. Int J Mol Sci. 2024;25:8202.
Article prepared by the Palmetto Peptides Research Team. Last Updated: March 19, 2026